S&P Futures
4,116.25 -31.50 (-0.76%) Dow Futures
33,780.00 -182.00 (-0.54%) Nasdaq Futures
12,499.00 -125.00 (-0.99%) Russell 2000 Futures
1,976.90 -16.60 (-0.83%) Crude Oil
74.15 +0.76 (+1.04%) Gold
1,884.60 +8.00 (+0.43%)
BrainStorm Cell Therapeutics In (GHDN.SG)
Chart Events
Performance Outlook
| Previous Close | 1.8905 |
| Open | 2.4580 |
| Bid | 2.6710 x 300000 |
| Ask | 2.7460 x 300000 |
| Day's Range | 2.4580 - 2.4580 |
| 52 Week Range | 1.2390 - 4.5710 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Mar 27, 2023 - Mar 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn's placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community. The specimens are being submitted to the biorepository in connection with a $500,000 grant previously awarded to BrainStorm by The ALS Association an
- PR Newswire
BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday, Jan. 9 at Biotech Showcase™ 2023 (Hilton San Francisco Union Square, Yosemite A, Ballroom Level). Company management will also be available for one-on-one investor meetings at the conference, which c
- PR Newswire
BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Stacy Lindborg to the role of Co-Chief Executive Officer. This promotion launches a targeted capability build which will be led by Dr. Lindborg, to hire and bring expertise inside BrainStorm, preparing for success.
